Loading...
•
Sep 30, 2020
Co-Diagnostics Q3 2020 Earnings Report
Announced Q3 2020 financial results and provided updates on company developments.
Key Takeaways
Co-Diagnostics announced financial results for the third quarter ended September 30, 2020, reporting widespread uptake of their COVID-19 test domestically and abroad. The company also received CE markings for both Logix Smart ABC and SARS-CoV-2 2-gene tests.
Co-Diagnostics continues to see widespread uptake of COVID-19 test domestically and abroad.
Customer and distributor bases are laying the foundation for a strong future.
Development projects have helped position Co-Diagnostics as a key player in the battle against the coronavirus pandemic.
Received two important CE markings that will allow ABC and COVID-19 2-gene tests to be sold as in vitro diagnostics in areas that accept CE markings as valid regulatory approval.
Co-Diagnostics
Co-Diagnostics
Forward Guidance
The company expects continued growth and expansion in the near future, driven by its technology platform and expanding menu of critical diagnostic tools.